Skip to content

EMEUNEWS

Search
  • Congress Topics
    • Basic Research
    • Imaging
    • Metabolic and Crystal Arthropathies
    • Paediatric Rheumatology
    • Rare and Autoinflammatory Diseases
    • Rheumatoid Arthritis I – Clinical (non-therapeutic)
    • Rheumatoid arthritis II – therapeutic
    • Spondyloarthritis I – non-therapeutic
    • Spondyloarthritis II – therapeutic
  • Featured Content
    • ACR Highlights
  • Press Review
    • Annals of the Rheumatic Diseases
    • RMD Open
    • Arthritis and Rheumatology
    • Rheumatology (Oxford)
    • Arthritis Research and Therapy
    • Arthritis Care and Research
    • Seminars in Arthritis and Rheumatism
    • The Lancet Rheumatology
    • Miscellaneous
  • About EMEUNEWS
  • About EMEUNET
  • Contact Us
  • Subscribe here!

Category: Miscellaneous

EMEUNET…

MISCELLANEOUS: OTHER RHEUMATOLOGY JOURNALS

12 May 202313 May 2023
December 2022 to March 2023 Authors: Juan C Sarmiento-Monroy Petri M et al (doi: 10.1016/S0140-6736(22)02546-6) assessed the efficacy and safety of baricitinib (BARI) in 775 adult patients with active SLE in a phase 3 study (SLE-BRAVE-II).…
Miscellaneous…

Miscellaneous

20 Jan 2023
August to November 2022 Author: Giacomo Cafaro Hannah et al. (doi: 10.3899/jrheum.220383) performed a systematic literature review (SLR) and meta-analysis (MA) to evaluate predictors of mortality in inflammatory myopathy-associated interstitial…

Seestrasse 240
CH 8802 Kilchberg (ZH)
Switzerland
emeunet@eular.ch
emeunet.eular.org

About EULAR
The European Alliance of Associations for Rheumatology, EULAR, is the organisation which represents the people with arthritis/rheumatism, health professionals in rheumatology (HPR) and scientific societies of rheumatology of all the European nations.
Visit website here

About EMEUNET
EMEUNET is an exciting community that started its activities in 2009, emanating from one of the objectives set by EULAR – "Bring on board high quality, young generation contributors in all EULAR activities".
Visit website here

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • Spotify
 

Loading Comments...